Literature DB >> 6231873

Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies.

J A Kovacs, J W Hiemenz, A M Macher, D Stover, H W Murray, J Shelhamer, H C Lane, C Urmacher, C Honig, D L Longo.   

Abstract

Clinical features of 49 episodes of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome were compared with those of 39 episodes in patients with other immunosuppressive diseases. At presentation patients with the syndrome were found to have a longer median duration of symptoms (28 days versus 5 days, p = 0.0001), lower mean respiratory rate (23.4 versus 30, p = 0.005), and higher median room air arterial oxygen tension (69 mm Hg versus 52 mm Hg, p = 0.0002). The survival rate from 1979 to 1983 was similar for the two groups (57% and 50% respectively). Patients with the syndrome had a higher incidence of adverse reactions to trimethoprim-sulfamethoxazole (22 of 34 versus 2 of 17, p = 0.0007). Survivors with the syndrome at initial presentation had a significantly lower respiratory rate, and higher room air arterial oxygen tension, lymphocyte count, and serum albumin level compared to nonsurvivors. Pneumocystis carinii pneumonia presents as a more insidious disease process in patients with the syndrome, and drug therapy in these patients is complicated by frequent adverse reactions.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6231873     DOI: 10.7326/0003-4819-100-5-663

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  140 in total

1.  Prevention of adverse events in hospitalized patients using an antimicrobial review program.

Authors:  B J Guglielmo; A D Luber; R L Corelli; J F Flaherty; R A Jacobs
Journal:  West J Med       Date:  1999-09

2.  Pneumocystis carinii: A review of an important opportunistic pathogen in AIDS.

Authors:  M J Gill; R Read
Journal:  Can J Infect Dis       Date:  1991

3.  Efficacy of clindamycin/primaquine versus trimethoprim/sulfamethoxazole in primary treatment of Pneumocystis carinii pneumonia.

Authors:  B Ruf; I Rohde; H D Pohle
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-03       Impact factor: 3.267

4.  Serum lactic dehydrogenase predicts mortality in patients with AIDS and Pneumocystis pneumonia.

Authors:  M L Lipman; E Goldstein
Journal:  West J Med       Date:  1988-10

5.  Dapsone treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome.

Authors:  J Mills; G Leoung; I Medina; P C Hopewell; W T Hughes; C Wofsy
Journal:  Antimicrob Agents Chemother       Date:  1988-07       Impact factor: 5.191

6.  Pneumocystis carinii antigenemia in acquired immunodeficiency syndrome.

Authors:  L W Pifer; B L Wolf; J J Weems; D R Woods; C C Edwards; R E Joyner
Journal:  J Clin Microbiol       Date:  1988-07       Impact factor: 5.948

7.  Lung function abnormalities in patients infected with the human immunodeficiency virus with and without overt pneumonitis.

Authors:  R J Shaw; C Roussak; S M Forster; J R Harris; A J Pinching; D M Mitchell
Journal:  Thorax       Date:  1988-06       Impact factor: 9.139

Review 8.  Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients.

Authors:  Martin Rodriguez; Jay A Fishman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

9.  Nucleotide sequence variation in Pneumocystis carinii strains that infect humans.

Authors:  C H Lee; J J Lu; M S Bartlett; M M Durkin; T H Liu; J Wang; B Jiang; J W Smith
Journal:  J Clin Microbiol       Date:  1993-03       Impact factor: 5.948

10.  Pneumocystis pneumonia in a non-HIV patient on chronic corticosteroid therapy: a question of prophylaxis.

Authors:  Michael J Plakke; Leena Jalota; Benjamin J Lloyd
Journal:  BMJ Case Rep       Date:  2013-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.